(S)-(+)-Rolipram is a chemical compound that has been studied for its potential in the treatment of various diseases, specifically those related to inflammation or the central nervous system. It is a selective phosphodiesterase 4 (PDE4) inhibitor that has shown potential in the treatment of various conditions such as depression, asthma, and chronic obstructive pulmonary disease (COPD). (S)-(+)-Rolipram's chemical name is (S)-(+)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone; its molecular formula is C16H21NO3, and its formula weight is 275.34 g/mol. Its CAS No is 85416-73-5.
Top Ten Keywords: (S)-(+)-Rolipram, PDE4 inhibitor, inflammation, central nervous system, depression, asthma, COPD, clinical trials, memory, neuroprotection.
Synonyms: 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone, CAS 85416-73-5.
Health Benefits of (S)-(+)-Rolipram: (S)-(+)-Rolipram has been shown to have potential health benefits in the treatment of various conditions. It has been studied for its potential in the treatment of depression, asthma, chronic obstructive pulmonary disease (COPD), and neurodegeneration. (S)-(+)-Rolipram has also been shown to have potential neuroprotective effects.
Potential Effects: (S)-(+)-Rolipram's potential effects include the treatment of depression, asthma, COPD, and neurodegenerative diseases such as Alzheimer's disease. It has also been shown to have potential neuroprotective effects, making it a promising compound in the treatment of various conditions related to the central nervous system. (S)-(+)-Rolipram has been shown to increase memory performance and cognitive function in preclinical studies.
Product Mechanism: (S)-(+)-Rolipram works by selectively inhibiting phosphodiesterase 4 (PDE4), an enzyme involved in the degradation of cyclic adenosine monophosphate (cAMP), a secondary messenger that plays a crucial role in intracellular signaling pathways. By inhibiting PDE4, (S)-(+)-Rolipram increases the levels of cAMP, leading to various downstream effects such as decreased inflammation or increased neuroprotection.
Safety: (S)-(+)-Rolipram has been tested in clinical trials and has been found to be relatively safe. Adverse effects were primarily mild or moderate in most instances, such as gastrointestinal discomfort, headache, and dizziness. (S)-(+)-Rolipram has also demonstrated low toxicity in non-clinical studies.
Side Effects: The side effects of (S)-(+)-Rolipram can vary depending on the patient and the condition being treated. Some of the most common side effects reported include gastrointestinal discomfort, nausea, headache, and dizziness. In rare instances, (S)-(+)-Rolipram has been associated with liver toxicity, so liver function should be monitored during treatment.
Dosing Information: The dosing information for (S)-(+)-Rolipram varies depending on the condition being treated and the patient. Researchers have tested various doses and dosing schedules to determine the most effective and safe therapeutic dose.
In conclusion, (S)-(+)-Rolipram is a selective PDE4 inhibitor that has shown potential in the treatment of various conditions related to inflammation or the central nervous system. Its mechanism of action involves the inhibition of PDE4, leading to various downstream effects such as decreased inflammation or increased neuroprotection. (S)-(+)-Rolipram has shown a favorable safety profile in clinical and non-clinical studies, with mild side effects such as gastrointestinal discomfort, headache, and dizziness. However, liver function should be monitored during treatment. Further research is necessary to determine its long-term safety and efficacy in the treatment of various conditions. (S)-(+)-Rolipram represents a promising new avenue for developing treatments for conditions related to inflammation and the central nervous system.
